Articles with public access mandates - Samantha PollardLearn more
Not available anywhere: 3
Balancing uncertainty with patient autonomy in precision medicine
S Pollard, S Sun, DA Regier
Nature Reviews Genetics 20 (5), 251-252, 2019
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Genome Canada
Developing data sharing models for health research with real-world data: a scoping review of patient and public preferences
A Hermansen, DA Regier, S Pollard
Journal of Medical Systems 46 (12), 86, 2022
Mandates: Genome Canada
Economic evaluation of rare diseases and the diagnostic odyssey
DA Regier, D Weymann, I Cromwell, M Ehman, S Pollard
Economic Evaluation in Genomic and Precision Medicine, 47-70, 2023
Mandates: Genome Canada
Available somewhere: 15
Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis: American College of …
S MacLean, S Mulla, EA Akl, M Jankowski, PO Vandvik, S Ebrahim, ...
Chest 141 (2), e1S-e23S, 2012
Mandates: US National Institutes of Health
In the public interest: assessing expert and stakeholder influence in public deliberation about biobanks
S MacLean, MM Burgess
Public Understanding of Science 19 (4), 486-496, 2010
Mandates: Canadian Institutes of Health Research, Genome Canada
Toward the diagnosis of rare childhood genetic diseases: what do parents value most?
S Pollard, D Weymann, J Dunne, F Mayanloo, J Buckell, J Buchanan, ...
European Journal of Human Genetics 29 (10), 1491-1501, 2021
Mandates: Genome Canada
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
DA Regier, S Pollard, M McPhail, T Bubela, TP Hanna, C Ho, HJ Lim, ...
NPJ Precision Oncology 6 (1), 76, 2022
Mandates: Canadian Cancer Society, Genome Canada
Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges
D Weymann, N Dragojlovic, S Pollard, DA Regier
Journal of community genetics 13 (5), 467-476, 2022
Mandates: Canadian Cancer Society
Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication
S Pollard, S Kalloger, D Weymann, S Sun, J Nuk, KA Schrader, DA Regier
Health Expectations 23 (4), 884-892, 2020
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research
Defining a core data set for the economic evaluation of precision oncology
S Pollard, D Weymann, B Chan, M Ehman, S Wordsworth, J Buchanan, ...
Value in Health 25 (8), 1371-1380, 2022
Mandates: Genome Canada
Clinical and cost outcomes following genomics‐informed treatment for advanced cancers
D Weymann, S Pollard, B Chan, E Titmuss, A Bohm, J Laskin, SJM Jones, ...
Cancer Medicine 10 (15), 5131-5140, 2021
Mandates: US National Institutes of Health, Genome Canada, Natural Sciences and …
Stakeholder perspectives on navigating evidentiary and decision uncertainty in precision oncology
S Pollard, J Dunne, S Costa, DA Regier
Journal of Personalized Medicine 12 (1), 22, 2022
Mandates: Genome Canada
Genomic testing for relapsed and refractory lymphoid cancers: understanding patient values
S Costa, DA Regier, AJN Raymakers, S Pollard
The Patient-Patient-Centered Outcomes Research 14, 187-196, 2021
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Genome Canada
Toward best practices for economic evaluations of tumour-agnostic therapies: A review of current barriers and solutions
D Weymann, S Pollard, H Lam, E Krebs, DA Regier
Value in Health, 2023
Mandates: Genome Canada
Development and early‐stage evaluation of a patient portal to enhance familial communication about hereditary cancer susceptibility testing: A patient‐driven approach
S Pollard, D Weymann, R Loewen, J Nuk, S Sun, KA Schrader, C Hessels, ...
Health Expectations, 2023
Mandates: Canadian Institutes of Health Research, Genome Canada
Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
DA Regier, B Chan, S Costa, DW Scott, C Steidl, JM Connors, A Karsan, ...
Cancers 14 (4), 908, 2022
Mandates: Genome Canada
Changes in healthcare costs following genome-wide sequencing for children with developmental disorders and early onset seizures in England and Canada
D Weymann, J Buckell, P Fahr, R Loewen, M Ehman, S Pollard, ...
Jama Network Open, 2024
Mandates: UK Medical Research Council, National Institute for Health Research, UK …
Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases in England and Canada
D Weymann, J Buckell, P Fahr, R Loewen, M Ehman, S Pollard, ...
JAMA Network Open 7 (7), e2420842-e2420842, 2024
Mandates: UK Medical Research Council, National Institute for Health Research, UK …
Publication and funding information is determined automatically by a computer program